Ironwood Pharmaceuticals Stock Today

IRWD Stock  USD 6.38  0.13  2.08%   


0 of 100

Very Weak

Odds Of Distress

Over 59

Above Average
Ironwood Pharmaceuticals is trading at 6.38 as of the 13th of June 2024, a 2.08 percent increase since the beginning of the trading day. The stock's lowest day price was 6.29. Ironwood Pharmaceuticals has over 59 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Ironwood Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of May 2024 and ending today, the 13th of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of February 2010
Health Care
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 158.96 M outstanding shares of which 22.66 M shares are currently shorted by private and institutional investors with about 7.82 trading days to cover. More on Ironwood Pharmaceuticals

Moving against Ironwood Stock

  0.49MZHOF Mizuho Financial Earnings Call This WeekPairCorr
  0.31ROIV Roivant Sciences Financial Report 26th of June 2024 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Ironwood Stock Highlights

ESG Sustainability
Thematic IdeaObamacare Repeal (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Obamacare Repeal, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.990.9398
Notably Up
Slightly volatile
Gross Profit Margin0.740.9964
Way Down
Very volatile
Total Current Liabilities289.9 M276.1 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total370.6 M541.3 M
Way Down
Slightly volatile
Total Assets499.5 M471.1 M
Notably Up
Slightly volatile
Total Current Assets356.5 M233.3 M
Way Up
Slightly volatile
Debt Levels
Ironwood Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ironwood Pharmaceuticals' financial leverage. It provides some insight into what part of Ironwood Pharmaceuticals' total assets is financed by creditors.
Ironwood Pharmaceuticals currently holds 715.54 M in liabilities with Debt to Equity (D/E) ratio of 0.78, which is about average as compared to similar companies. Ironwood Pharmaceuticals has a current ratio of 25.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ironwood Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Stock Based Compensation

23.83 Million
Ironwood Pharmaceuticals (IRWD) is traded on NASDAQ Exchange in USA. It is located in 100 Summer Street, Boston, MA, United States, 02110 and employs 267 people. Ironwood Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 993.48 M. Ironwood Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 158.96 M outstanding shares of which 22.66 M shares are currently shorted by private and institutional investors with about 7.82 trading days to cover. Ironwood Pharmaceuticals currently holds about 504.36 M in cash with 183.43 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29.
Check Ironwood Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
The majority of Ironwood Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ironwood Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ironwood Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ironwood Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Ironwood Ownership Details

Ironwood Stock Institutional Holders

InstituionRecorded OnShares
Man Group Plc2024-03-31
Brown Capital Management, Llc2024-03-31
2.7 M
Morgan Stanley - Brokerage Accounts2024-03-31
2.7 M
Nuveen Asset Management, Llc2024-03-31
1.8 M
Kynam Capital Management, Lp2024-03-31
1.6 M
Northern Trust Corp2024-03-31
1.5 M
Deutsche Bank Ag2024-03-31
1.5 M
Jupiter Asset Management Limited2024-03-31
1.5 M
Charles Schwab Investment Management Inc2024-03-31
1.4 M
Blackrock Inc2024-03-31
24.2 M
Vanguard Group Inc2024-03-31
19.5 M
View Ironwood Pharmaceuticals Diagnostics

Ironwood Pharmaceuticals Historical Income Statement

At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M. View More Fundamentals

Ironwood Stock Against Markets

Ironwood Pharmaceuticals Corporate Management

Thomas McCourtChief Commercial Officer and Sr. VP of Marketing and SalesProfile
Jana NoeldekeBasel LeaderProfile
Ronald SilverCorporate OfficerProfile
Marcel MoulaisonVice OperationsProfile
Beth CalitriHead RelationsProfile
Sravan EmanyPrincipal VPProfile

Additional Information and Resources on Investing in Ironwood Stock

When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.